US-based Inhalon Biopharma is set to launch a trial of its at-home nebulised treatment for respiratory syncytial virus (RSV) ...

In the wake of multiple cases of human metapneumovirus (hMPV) in India, multiple questions about its causes and symptoms seem ...

Human metapneumovirus (hMPV) cases continue to be reported in several states across India, although the number of cases is ...

Human Metapneumovirus (HMPV) is a respiratory virus that may not be on most folk’s radars, but it’s more common than you ...

A virus rapidly spreading in China is also circulating in the United States, causing concern among health experts.

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study.

(Alliance News) - hVIVO PLC on Monday said it has signed a contract with Inhalon Biopharma Inc to test its antiviral candidate to treat respiratory syncytial virus. The London-based contract research ...

New at-home RSV treatment represents a potential breakthrough in addressing the burden of respiratory diseases, especially in vulnerable pediatric and elderly ...

Human metapneumovirus (hMPV) has been hitting the headlines recently as one of the lesser-known winter illnesses that can ...

S-337395 is an investigational oral antiviral candidate for RSV infection that inhibits the activity of the L protein, which is essential for virus replication. 1,2 Furthermore, this drug has received ...

The main signs of HMPV, a highly infectious virus that has apparently swept over regions of northern China in recent weeks, ...

Senior health experts are urging people to steer clear of medical facilities if they exhibit symptoms and to don face masks ...